High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma

Alessandro M. Gianni, Marco Bregni, Salvatore Siena, Cristina Brambilla, Massimo Di Nicola, Fabrizio Lombardi, Lorenza Gandola, Corrado Tarella, Alessandro Pileri, Fernando Ravagnani, Pinuccia Valagussa, Gianni Bonadonna, Angelika C. Stern, Michele Magni, Daniele Caracciolo

Research output: Contribution to journalArticle

Abstract

Background: We compared a regimen of six chemotherapeutic agents administered sequentially at high doses, followed by myeloablative treatment and bone marrow transplantation, with a regimen of methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin (MACOP-B) as initial or salvage treatment for adults with diffuse large-cell lymphoma. Methods: Ninety-eight eligible patients with diffuse large-cell lymphoma of the B- cell type were randomly assigned to receive either MACOP-B (50 patients) or high-dose sequential therapy (48 patients). If the assigned treatment failed, the study design allowed patients to cross over to the other treatment group. Results: After a median follow-up of 55 months, the patients given high-dose sequential therapy, as compared with those treated with MACOP-B, had significantly higher rates of complete response (96 percent vs. 70 percent, P=0.001), freedom from disease progression (84 percent vs. 49 percent, P

Original languageEnglish
Pages (from-to)1290-1297
Number of pages8
JournalNew England Journal of Medicine
Volume336
Issue number18
DOIs
Publication statusPublished - 1997

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma'. Together they form a unique fingerprint.

Cite this